Search by Drug Name or NDC
NDC 00093-2013-12 Sumatriptan 4 mg/.5mL Details
Sumatriptan 4 mg/.5mL
Sumatriptan is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Teva Pharmaceuticals USA Inc. The primary component is SUMATRIPTAN SUCCINATE.
MedlinePlus Drug Summary
Sumatriptan injection is used to treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Sumatriptan injection is also used to treat the symptoms of cluster headaches (severe headaches usually on one side of the head or around one eye). Sumatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine or cluster headaches. Sumatriptan does not prevent migraine attacks or reduce the number of headaches you have.
Related Packages: 00093-2013-12Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Sumatriptan Injection
Product Information
| NDC | 00093-2013 |
|---|---|
| Product ID | 0093-2013_b8128b50-7bfe-4ec9-8c1e-aa3141d8e917 |
| Associated GPIs | 6740607010D510 |
| GCN Sequence Number | 060499 |
| GCN Sequence Number Description | sumatriptan succinate PEN INJCTR 4 MG/0.5ML SUBCUT |
| HIC3 | H3F |
| HIC3 Description | ANTIMIGRAINE PREPARATIONS |
| GCN | 26666 |
| HICL Sequence Number | 006587 |
| HICL Sequence Number Description | SUMATRIPTAN SUCCINATE |
| Brand/Generic | Generic |
| Proprietary Name | Sumatriptan |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | sumatriptan succinate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 4 |
| Active Ingredient Units | mg/.5mL |
| Substance Name | SUMATRIPTAN SUCCINATE |
| Labeler Name | Teva Pharmaceuticals USA Inc |
| Pharmaceutical Class | Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA078319 |
| Listing Certified Through | n/a |
Package
NDC 00093-2013-12 (00093201312)
| NDC Package Code | 0093-2013-12 |
|---|---|
| Billing NDC | 00093201312 |
| Package | 2 SYRINGE in 1 CARTON (0093-2013-12) / .5 mL in 1 SYRINGE (0093-2013-34) |
| Marketing Start Date | 2016-06-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 146.932 |
| Pricing Unit | ML |
| Effective Date | 2024-01-17 |
| NDC Description | SUMATRIPTAN 4 MG/0.5 ML INJECT |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |